SQLite Web: event_store.db

Update row sig_7f7d0a834241 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000003.txt","as_of":"2026-04-08T19:57:42.365437+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000003.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000003.txt","article_chars":2096,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_fe91666635700908","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000003.txt","content_type":"text/plain","enriched_at":"2026-04-09T01:23:04.130392+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000003.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000003.txt","source_event_id":"evt_acf3e2e8a369","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"e1b0fbed3c7d2cf6","kind":"sec_filing","published_at":"20260407","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-07","2026-04-06","2025-11-17","2018-05-09","2028-05-09","2013-02-20","2008-06-25"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"high","symbol":"TVTX","type":"issuer"},{"asset_class":"equity","name":"Roy D. Baynes","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Elizabeth E. Reed","relevance":"medium","symbol":"","type":"attorney_in_fact"}],"event_type":"listing","information_gaps":["The cleaned text is truncated/garbled around some numeric fields (e.g., exact share counts and total proceeds are not fully clear beyond the repeated '10,000' and prices 26.52 and 33).","The filing type is identified as Form 4, but the signal headline 'TVTX filed 4' does not specify whether this is the only transaction or whether multiple transactions are included beyond the two common stock entries shown.","No explicit total number of shares sold or total dollar value is clearly stated in the provided text excerpt."],"key_facts":["SEC filing: Form 4 filed as of 2026-04-07; conforming period of report: 2026-04-06.","Issuer: Travere Therapeutics, Inc. (TVTX).","Reporting owner: Roy D. Baynes.","Transaction described as a sale made pursuant to a written plan adopted on November 17, 2025, meeting Rule 10b5-1(c) requirements.","The sale consists of shares underlying a stock option grant to the reporting person on May 9, 2018.","The stock option is stated as fully vested and exercisable.","The filing includes two common stock sale entries with prices shown as 26.52 and 33 (amounts shown as 10,000 shares each, with additional numeric fields present in the text).","Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact, dated 2026-04-07."],"numeric_claims":[{"label":"Form 4 filed as of date","value":"2026-04-07"},{"label":"Conformed period of report","value":"2026-04-06"},{"label":"Rule 10b5-1 plan adoption date","value":"2025-11-17"},{"label":"Stock option grant date","value":"2018-05-09"},{"label":"Option status","value":"fully vested and exercisable"},{"label":"Common stock sale price (entry 1)","value":"26.52"},{"label":"Common stock sale price (entry 2)","value":"33"},{"label":"Shares shown per entry","value":"10,000"}],"primary_claim":"Form 4 (filed 2026-04-07) by Travere Therapeutics, Inc. reports Roy D. Baynes selling shares underlying a fully vested, exercisable stock option under a Rule 10b5-1(c) plan.","relevance_score":0.45,"sentiment":"neutral","source_quality":"medium","summary":"Travere Therapeutics, Inc. (TVTX) filed a Form 4 on 2026-04-07 reporting a sale of shares by reporting owner Roy D. Baynes. The filing states the sale was made under a Rule 10b5-1(c) plan and relates to shares underlying a fully vested, exercisable stock option granted May 9, 2018.","topics":["SEC Form 4","insider transaction","Rule 10b5-1(c)","stock option exercise/sale","common stock"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260407","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed 4","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001680739-26-000003.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel